MET and non-small cell lung carcinoma: Alterations in the mesenchymal-epithelial transition (MET) gene have been recognized as a primary oncogenic driver in NSCLC, and mutations leading to MET exon 14 (METex14) skipping are the most reported oncogenic MET mutations, occurring in around 0.9–4% of patients with NSCLC (3–5).